Du är här


Bionor Pharma ASA: Bionor granted up to NOK 9.2 million from Research Council of Norway to further advance Vacc-4x in a combination treatment regimen



Bionor granted up to NOK 9.2 million from Research Council of Norway to
further advance Vacc-4x in a combination treatment regimen

(Oslo, Norway, 1 February 2016) Bionor Pharma ASA (OSE:BIONOR) announces today
that the Research Council of Norway (RCN) through its BIA Program
(Brukerstyrt Innovasjonsarena), has awarded the company up to NOK 9.2 million
to partially fund an exploratory Phase I/II trial of Vacc-4x in combination
with an immune regulating agent. The BIA program supports high-quality R&D
projects with good business and socio-economic potential.

Bionor's strategy is to advance Vacc-4x in combination with other medicines in
order to significantly contribute to a functional HIV cure, and has, as a
first step, adopted a "Shock&Kill" clinical strategy employing Vacc-4x
("Kill") as a core treatment in combination with a latency reversing agent
("Shock"). Bionor anticipates that an immune regulating agent will also be
needed as part of a triple regimen combination treatment, to achieve
functional cure.

This study will test an HIV-specific broadly neutralizing antibody (bNab) as a
candidate third component. The bNab is expected to complement the effects of
Vacc-4x by blocking infectivity of virus particles produced on latency
reversal. Vacc-4x must be tested with the latency reversing agent and bNab
separately to confirm safety and effect before they can be tested in a later
stage clinical trial of a triple regimen as a future therapy for functional
HIV cure.

The Grant from RCN is expected to correspond to around 40% of the total trial
cost incurred in the trial period from 2016 to 2019.

Further information

David Horn Solomon, President and CEO, +45 22 20 63 00,dhs@bionorpharma.com

Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by reducing latent HIV reservoir and further demonstrated
control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway, and also has
offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo
Børs (OSE:BIONOR). More information about Bionor is available

RCN Grant February 2016


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.